Last reviewed · How we verify

Rate Control

Icahn School of Medicine at Mount Sinai · Phase 3 active Small molecule

Rate Control is a therapeutic approach designed to manage heart rate in patients with atrial fibrillation by slowing atrioventricular node conduction.

Rate Control is a therapeutic approach designed to manage heart rate in patients with atrial fibrillation by slowing atrioventricular node conduction. Used for Atrial fibrillation with rapid ventricular response.

At a glance

Generic nameRate Control
Also known asBeta-blocker, Calcium channel blockers, Digoxin, Toprol, Tenormin
SponsorIcahn School of Medicine at Mount Sinai
ModalitySmall molecule
Therapeutic areaCardiovascular
PhasePhase 3

Mechanism of action

Rate control therapy aims to reduce the ventricular response rate in atrial fibrillation patients to improve symptoms and reduce cardiovascular complications, without necessarily converting the arrhythmia to normal sinus rhythm. This is typically achieved through pharmacological agents that slow conduction through the AV node, such as beta-blockers, calcium channel blockers, or digoxin, or through device-based interventions.

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results